Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vemurafenib and Cobimetinib in Advanced BRAFV600 Mutant Melanoma
NCT01813214Phase 2Terminated
- Sponsor
- Georgetown University
- Start
- Mar 2013
- Primary completion
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of cobimetinib in melanoma (2 arms), sponsored by Georgetown University. Primary endpoint: Time Course of T Cell Infiltration at Day 29. Started Mar 2013; status: terminated.
02
Drugs
cobimetinib
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT01813214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01813214.